

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/160133 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) C07K 1/18 (2006.01)
A61K 38/17 (2006.01) C07K 1/22 (2006.01)

(21) International Application Number:

PCT/US2020/015659

(22) International Filing Date:

29 January 2020 (29.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/798,903 30 January 2019 (30.01.2019) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **LUO, Quanzhou**; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **WOEHLE, Diana**; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **JERUMS, Matthew**; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **KUHNS, Scott**; c/o

Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **HAN, Xuejun**; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **MATTHIES, Kelli M.G.**; c/o Amgen Inc., Law Department – Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **MAH, Angie S.**; AMGEN INC., Law Department – Patent Operations M/S 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF

(57) Abstract: The present disclosure relates to aflibercept, in particular, attributes of aflibercept. Also provided herein are methods of characterizing and modifying the attributes of aflibercept and compositions comprising aflibercept with particular attributes.

Figure 1



Clipping (M10Y, Y92L, R153D) ✂
Deamidation (84, 99) ●
N-linked glycosylation (36, 68, 123, 196, 282) ✦
Met Oxidation (10, 20, 192) ●
Intra-chain disulfide bond —
Inter-chain disulfide bond - - -

WO 2020/160133 A1

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*